Human granulocytic anaplasmosis
|Human granulocytic anaplasmosis|
|Classification and external resources|
|eMedicine||med/3391 ped/655 emerg/159|
Human granulocytic anaplasmosis (HGA) (previously known as Human granulocytic ehrlichiosis, or HGE ) is an infectious disease caused by Anaplasma phagocytophilum, an obligate intracellular bacterium that is typically transmitted to humans by at least three kinds of ticks, including Ixodes scapularis, Ixodes pacificus, and Dermacentor variabilis. These ticks also transmit Lyme disease and other diseases.
Ecology and epidemiology
A. phagocytophilum is transmitted to humans by Ixodes ticks. These ticks are found in the US, Europe, and Asia. In the US, I. scapularis is the tick vector in the East and Midwest states, and I. pacificus in the Pacific Northwest.
The major mammalian reservoir for A. phagocytophilum in the eastern United States is the white-footed mouse, Peromyscus leucopus. Although white-tailed deer harbor A. phagocytophilum, evidence suggests that they are not a reservoir for the strains that cause HGA.
Anaplasma phagocytophilum shares its tick vector with other human pathogens, and about 10% of patients with HGA show serologic evidence of coinfection with Lyme disease, babesiosis, or tick-borne meningoencephalitis.
Symptoms may include fever, severe headache, muscle aches (myalgia), chills and shaking, similar to the symptoms of influenza. Symptoms may also include nausea, vomiting, loss of appetite, weight loss, abdominal pain, cough, diarrhea, aching joints, sensitivity to light, weakness, fatigue, change in mental status(extreme confusion, memory loss,inability to comprehend environment- interaction, reading, etc.), and temporary loss of basic motor skills (no permanent cases have been reported). Symptoms may be minor, as evidenced by surveillance studies in high-risk areas. GI symptoms occur in less than half of patients and a skin rash is seen in less than 10% of patients. It is also characterized by thrombocytopenia, leukopenia, and elevated serum transaminase levels in the majority of infected patients.
Even though people of any age can get human anaplasmosis, it is usually more severe in the aging or immune-compromised. Some severe complications may include respiratory failure, renal failure and secondary infections.
Clinically, HGA is essentially indistinguishable from Human monocytic ehrlichiosis, the infection caused by Ehrlichia chaffeensis, and other tick-borne illnesses such as Lyme disease may be suspected. As Ehrlichia serologies can be negative in the acute period, PCR is very useful for diagnosis.
Treatment and Prevention
Doxycycline is the treatment of choice. If anaplasmosis is suspected, treatment should not be delayed while waiting for a definitive laboratory confirmation, as prompt doxycycline therapy has been shown to improve outcomes. Presentation during early pregnancy can complicate treatment. Doxycycline compromises dental enamel during development. Although rifampin is indicated for post-delivery pediatric and some doxycycline-allergic patients, it is teratogenic. Rifampin is contraindicated during conception and pregnancy. Currently, there is no vaccine against human granulocytic anaplasmosis.
Although the infectious agent is known to be from the Anaplasma genus, the term "human granulocytic ehrlichiosis" (HGE) is often used, reflecting the prior classification of the organism. E. phagocytophilum and E. equi were reclassified as Anaplasma phagocytophilum.
- Human monocytic ehrlichiosis
- Human ewingii ehrlichiosis
- Ehrlichiosis (canine)
- Ticks of domestic animals
- CDC Emerging Infectious Diseases for more information about HGE
- Malik A, Jameel M, Ali S, Mir S (2005). "Human granulocytic anaplasmosis affecting the myocardium". J Gen Intern Med 20 (10): 958. doi:10.1111/j.1525-1497.2005.00218.x. PMC 1490240. PMID 16191146.
- Human Anaplasmosis Basics - Minnesota Dept. of Health
- PMID: Lee HC, Kioi M, Han J, Puri RK, Goodman JL (September 2008). "Anaplasma phagocytophilum-induced gene expression in both human neutrophils and HL-60 cells". Genomics 92 (3): 144–51. doi:10.1016/j.ygeno.2008.05.005. PMID 18603403.
- Dumler JS, Madigan JE, Pusterla N, Bakken JS (July 2007). "Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment". Clinical Infectious Diseases 45 (Suppl 1): S45–51. doi:10.1086/518146. PMID 17582569.
- Massung RF, Courtney JW, Hiratzka SL, Pitzer VE, Smith G, Dryden RL (October 2005). "Anaplasma phagocytophilum in white-tailed deer". Emerging Infectious Diseases 11 (10): 1604–6. doi:10.3201/eid1110.041329. PMID 16318705.
- Dumler JS, Choi KS, Garcia-Garcia JC et al. (December 2005). "Human granulocytic anaplasmosis and Anaplasma phagocytophilum". Emerging Infectious Diseases 11 (12): 1828–34. doi:10.3201/eid1112.050898. PMC 3367650. PMID 16485466.
- Murray, Patrick R.; Rosenthal, Ken S.; Pfaller, Michael A. Medical Microbiology, Fifth Edition. United States: Elsevier Mosby, 2005
- Prince LK, Shah AA, Martinez LJ, Moran KA (August 2007). "Ehrlichiosis: making the diagnosis in the acute setting". Southern Medical Journal 100 (8): 825–8. doi:10.1097/smj.0b013e31804aa1ad. PMID 17713310.
- Hamburg BJ, Storch GA, Micek ST, Kollef MH (March 2008). "The importance of early treatment with doxycycline in human ehrlichiosis". Medicine 87 (2): 53–60. doi:10.1097/MD.0b013e318168da1d. PMID 18344803.
- Muffly T, McCormick TC, Cook C, Wall J (2008). "Human granulocytic ehrlichiosis complicating early pregnancy". Infect Dis Obstet Gynecol 2008: 359172. doi:10.1155/2008/359172. PMC 2396214. PMID 18509484.
- Krause PJ, Corrow CL, Bakken JS (September 2003). "Successful treatment of human granulocytic ehrlichiosis in children using rifampin". Pediatrics 112 (3 Pt 1): e252–3. doi:10.1542/peds.112.3.e252. PMID 12949322.